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Introduction
Neonatal diabetes mellitus develops before 6 months of age and is 
caused by reduced pancreatic β cell number (reduced formation/
increased destruction) or impaired β cell function. Previous stud-
ies have shown that neonatal diabetes is most likely caused by a 
mutation in a single gene, rather than being autoimmune type 1 
diabetes (1, 2). To date, 30 genetic causes have been described, 
which account for 82% of cases (3–9). Additional clinical features 
are often present in patients with neonatal diabetes, with 18% of 
them having neurological symptoms (3). This is not surprising, as 
β cells and neurons have key genes and cellular functions in com-
mon (10, 11).
Pathogenic variants in 11 genes (ABCC8, KCNJ11, CNOT1, 
EIF2AK3, SLC19A2, IER3IP1, PTF1A, NEUROD1, MNX1, WFS1, 
and NKX2-2) are known to cause neonatal diabetes with neuro-
logical features, ranging from developmental delay to structural 
abnormalities such as microcephaly (3, 4). Recently, pathogenic 
variants in 3 genes (TRMT10A [ref. 12], PPP1R15B [ref. 13], and 
EIF2S3 [refs. 14, 15]) were reported to cause young- or adult-onset 
diabetes and microcephaly. The overlap between genes causing 
diabetes and neurological features highlights shared pathways 
that are critically important for development (CNOT1, PTF1A, 
Neonatal diabetes is caused by single gene mutations reducing pancreatic β cell number or impairing β cell function. 
Understanding the genetic basis of rare diabetes subtypes highlights fundamental biological processes in β cells. We 
identified 6 patients from 5 families with homozygous mutations in the YIPF5 gene, which is involved in trafficking between 
the endoplasmic reticulum (ER) and the Golgi. All patients had neonatal/early-onset diabetes, severe microcephaly, and 
epilepsy. YIPF5 is expressed during human brain development, in adult brain and pancreatic islets. We used 3 human β cell 
models (YIPF5 silencing in EndoC-βH1 cells, YIPF5 knockout and mutation knockin in embryonic stem cells, and patient-
derived induced pluripotent stem cells) to investigate the mechanism through which YIPF5 loss of function affects β cells. 
Loss of YIPF5 function in stem cell–derived islet cells resulted in proinsulin retention in the ER, marked ER stress, and β 
cell failure. Partial YIPF5 silencing in EndoC-βH1 cells and a patient mutation in stem cells increased the β cell sensitivity 
to ER stress–induced apoptosis. We report recessive YIPF5 mutations as the genetic cause of a congenital syndrome of 
microcephaly, epilepsy, and neonatal/early-onset diabetes, highlighting a critical role of YIPF5 in β cells and neurons. We 
believe this is the first report of mutations disrupting the ER-to-Golgi trafficking, resulting in diabetes.
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ER to the Golgi compartment is compromised (18, 19). The ER 
stress response aims at slowing down translation of new pro-
teins (through PERK-mediated eIF2α phosphorylation), while 
increasing the ER’s protein folding ability. Mutations in 5 genes 
that dysregulate signaling in the PERK branch of the ER stress 
response cause β cell dysfunction and apoptosis by perturbing 
translational control.
Identifying the genes causing syndromic forms of neonatal 
diabetes that include neurological features can highlight path-
ways important for development and function of β cells and 
neurons, giving insights into the pathogenesis of more common 
diseases. In this study, we used genome sequencing to identify 
recessive pathogenic variants in YIPF5 as the genetic cause of 
a congenital syndrome characterized by neonatal/early-onset 
diabetes, severe microcephaly, and epilepsy. Functional studies 
in human β cell models highlight the importance of ER-to-Golgi 
trafficking in β cells and neurons.
NEUROD1, MNX1, and NKX2-2) and function (ABCC8, KCNJ11, 
EIF2AK3, SLC19A2, IER3IP1, WFS1, TRMT10A, PPP1R15B, 
EIF2S3) of both β cells and neurons.
One of the pathways known to be crucial for the function of 
both β and brain cells is the endoplasmic reticulum (ER) stress 
response. Pathogenic variants in 8 genes known to be involved 
in regulating the ER stress response have been found to cause 
diabetes (ranging from neonatal to adolescent/adult-onset 
diabetes), often associated with neurological features (6, 16). 
The ER stress response is an adaptive pathway that is trig-
gered when there is an imbalance in the ability of the ER to 
fold proteins and the cellular protein folding demand, leading 
to accumulation of unfolded or misfolded proteins in the ER. 
This can happen when a genetic mutation results in a wrong-
ly folded protein that is unable to exit the ER, as happens with 
dominant INS mutations causing diabetes (17). ER stress can 
also be triggered when transport of folded proteins from the 
Table 1. Clinical features of patients with YIPF5 mutations
Patient ID Patient I Patient II Patient IIIa Patient IIIb Patient IV Patient V
Gene YIPF5 YIPF5 YIPF5 YIPF5 YIPF5 YIPF5
Mutation (cDNA) c.542C>T c.317_319del c.293T>G c.293T>G c.652T>A c.290G>T
Protein p.(Ala181Val) p.(Lys106del) p.(Ile98Ser) p.(Ile98Ser) p.(Trp218Arg) p.(Gly97Val)
Consanguinity (parental relation) Yes (first cousins) Yes (first cousins) Yes (first cousins) Yes (first cousins) Yes (second cousins) Yes (first cousins)
Country Turkey India Turkey Turkey Turkey India
Sex Male Male Female Female Female Male
















Age at diagnosis of diabetes 9 weeks 15 weeks 15 months 8.5 months 4 weeks 23 weeks
Insulin dose (U/kg/d) 0.73 1.7 0.87 0.8 0.77 0.9
Hemoglobin A1c 8.7% N/A 8.7% 8.7% 10.7% 14.8%
C-peptide (pmol/L) 99 N/A 95 147 46 N/A
Neurological features
Age at diagnosis of epilepsy 2 months; no episodes 
since age 3 months
4 months 6 months 7 months 1 month 3 months
Epilepsy features and treatment Generalized tonic clonic 
seizures; medication: 
phenobarbitone and 
levetiracetam, stopped at 
age 2 years





Generalized tonic clonic 
seizures; medication: 
clonazepam and valproic 
acid
Generalized tonic clonic 
seizures; medication: 
vigabatrin and valproic 
acid




Generalized tonic clonic 
seizures; medication: 
levetiracetam
Severe microcephaly Yes Yes Yes Yes Yes Yes
Occipital frontal circumference  
at first assessment (SDS)
35 cm at 2 months  
(–3.4)
39 cm at 4 months  
(–2.5)
N/A 40.5 cm at 11 months  
(–3.8)
N/A 36.5 cm at 7 months  
(–6.3)
Occipital frontal circumference  
at last assessment (SDS)
41 cm  
(–5.1)
37.5 cm  
(–8.1)
47 cm  
(–7.4)
47.7 cm  
(–5.9)
37 cm  
(–6.1)
N/A
Brain MRI Normal structure N/A Bilaterally increased 
lateral ventricles size 
Normal structure Normal structure N/A
Developmental delay (DD) Neuromotor development 
normal at 5 years
Severe DD Severe DD, unable 
to speak and walk 
independently at  
21 years
Severe DD, unable 
to speak and walk 
independently at  
15 years
Severe DD, unable 
to speak and walk 
independently at  
5.5 years
Severe DD
All variants are homozygous and are described according to Human Genome Variation Society guidelines based on the longest isoform, NM_001024947.3. 
CSF, cerebrospinal fluid; N/A, not available; SDS, standard deviation score.
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excluded. Since both patients were born to consanguineous (first 
cousins) parents and the phenotype was strikingly similar, we 
hypothesized that both were affected by the same autosomal 
recessive condition. We therefore focused our analysis on homo-
zygous rare coding variants in shared genes.
Results
Genetic analysis. Genome sequencing was performed for 2 unre-
lated probands diagnosed with neonatal diabetes, epilepsy, and 
severe microcephaly (patients I and II in Table 1 and Figure 1A) 
in whom mutations in known neonatal diabetes genes had been 
Figure 1. Identification of homozygous YIPF5 mutations in 6 patients 
with neonatal diabetes, severe microcephaly, and epilepsy. (A) Par-
tial pedigrees and summary of clinical features of the 6 patients with 
homozygous YIPF5 mutations. Age at diagnosis of diabetes and head 
circumference standard deviation below the mean are given in parenthe-
ses. (B) Schematic representation of the YIPF5 ER transmembrane protein 
using the CCTOP in silico predictor (http://cctop.enzim.ttk.mta.hu/). Note 
that there is uncertainty regarding YIPF5 transmembrane predictions 
and the position of the p.Trp218 residue is predicted to be cytoplasmic by 
UniProtKB (https://www.uniprot.org/).
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to affect residues located in the cytoplasmic domain, while the 
p.(Ala181Val) and p.(Trp218Arg) variants affect residues located 
in the third and fourth transmembrane domain, respectively (Fig-
ure 1B). The nature and position of the variants are consistent with 
at least a partial loss of protein function.
Clinical evaluation. The clinical features of the 6 patients are 
summarized in Table 1. All had severe microcephaly (median stan-
dard deviation score –6.2, IQR –6.5 to 6.1; Supplemental Figure 
1B), epilepsy diagnosed in the neonatal period (range 1–7 months), 
and neonatal/early-onset diabetes (age at diagnosis range 4 
weeks to 20 months) that was treated with a full replacement dose 
of insulin. For all 6 patients, the birth weight was low (median 
standard deviation score –1.85 (–1.99 to –1.72)), consistent with 
reduced insulin secretion in utero.
Patient II died at the age of 1.3 years. There was a family histo-
ry of 4 siblings (2 female and 2 male) diagnosed with neonatal dia-
betes, epilepsy, and microcephaly who had died in infancy. DNA 
was not available for these individuals.
Five individuals (II, IIIa, IIIb, IV, and V) were reported to have 
severe developmental delay, while neuromotor development was 
reported to be normal in patient I, who was 5 years of age at time 
of writing. No other clinical features were reported.
There was no significant family history of diabetes for any of the 
patients. Patient IV’s father, who was diagnosed with type 2 diabetes 
and was being treated with oral hypoglycemic agents, was the only 
one of the patients’ parents to be affected with diabetes.
YIPF5 is expressed in human islets and brain. YIPF5 mRNA 
expression was evaluated in human tissues by quantitative 
(qPCR). YIPF5 was ubiquitously expressed, with abundant expres-
sion in pancreatic tissue, islets, β cells, and brain (Figure 2A).
The expression pattern of YIPF5 during brain development 
was examined by in situ hybridization in human fetal brain 
samples encompassing stages 12 to 21 gestational weeks (Fig-
ure 2B and data not shown). This revealed significant broad 
expression of YIPF5 in the developing cortex at all stages exam-
ined but most strikingly at 12 gestational weeks. Expression 
Rare homozygous coding variants in 28 genes were iden-
tified in patient I, who had genome-wide homozygosity of 
11.7% calculated from genome sequencing data. Patient II had 
genome-wide homozygosity of 6.9%, and rare homozygous 
coding variants were identified in 10 genes (see Supplemental 
Tables 1 and 2 and Supplemental Figure 1A; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI141455DS1). The only gene in common in both individuals 
was YIPF5, with patient I being homozygous for a missense, 
p.(Ala181Val), and patient II harboring a homozygous in-frame 
deletion variant, p.(Lys106del).
Neither variant was listed in the gnomAD database (>120,000 
individuals [ref. 20], accessed May 18, 2020), and both affect resi-
dues that are highly conserved across species (up to Saccharomyces 
cerevisiae). The p.(Ala181Val) amino acid change was predicted to 
be likely to affect protein function by 2 of 4 tools used to assess 
the effect of missense variants, Sorting Intolerant from Tolerant 
(SIFT) (21) and MutationTaster (22) (Supplemental Table 3). Test-
ing for the mutations in parental samples confirmed that the unaf-
fected parents were heterozygous for the mutations.
To replicate this finding in a larger unselected cohort, we ana-
lyzed the coding regions and exon-intron boundaries of the YIPF5 
gene in a further 187 cases diagnosed with diabetes before the age 
of 12 months (10 also had microcephaly) who did not have a muta-
tion in known monogenic diabetes genes. We identified 3 homo-
zygous YIPF5 missense mutations, p.(Ile98Ser), p.(Trp218Arg), 
and p.(Gly97Val), in 3 cases. Testing for the mutations in family 
members confirmed that the parents were all heterozygous for the 
mutations and that patient III’s affected sister was also homozy-
gous for the p.(Ile98Ser) variant (Figure 1A). The 3 variants are not 
listed in gnomAD, affect residues that are conserved though spe-
cies up to S. cerevisiae, and are predicted by 4 of 4 in silico tools — 
Align GVGD (23), SIFT, PolyPhen-2 (24), and MutationTaster — to 
be likely to affect YIPF5 protein (Supplemental Table 3).
Protein domain analysis using CCTOP (25) predicted 3 of 
the variants, the p.(Gly97Val), p.(Ile98Ser), and p.(Lys106del), 
Figure 2. YIPF5 is expressed in human pancreatic tissue and brain. (A) YIPF5 mRNA expression was measured by qPCR in human tissues (n = 2–3), EndoC-
βH1 cells (n = 15), and human islets (n = 4) and normalized to the geometric mean of the reference genes ACTB, GAPDH, and OAZ1. (B) In situ hybridization 
of YIPF5 in human fetal cortex at gestational week 12. Expression is found in the ventricular zone (VZ), intermediate zone (IZ), and cortical plate (CP) as well 
choroid plexus (ch) (antisense probe, right). No signal was detected when the sense probe was used (negative control, left). Scale bar: 100 μm.
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Figure 3. YIPF5 deficiency does not affect insulin secretion but sensitizes β cells to ER stress–induced apoptosis. (A–C) EndoC-βH1 cells were transfected with 
siRNA against YIPF5 (si1) or control siRNA (siCT) for 48 hours and incubated with 0 or 20 mM glucose or 20 mM glucose plus 10 μM forskolin (FSK). (A) YIPF5 
mRNA expression by qPCR. (B) Insulin content normalized for total protein content. (C) Insulin secretion expressed as percentage of total insulin content. (D and 
E) EndoC-βH1 cells were transfected with 2 siRNAs against YIPF5 (si1 and si2) or control siRNA (siCT) for 48 hours and exposed or not (CTL) to thapsigargin (Tha) 
for 40 hours or brefeldin A (BFA) for 16 hours (n = 4). Apoptosis was evaluated by staining with DNA-binding dyes (n = 4) (D) or luminescence produced by annexin 
V binding (RealTime-Glo Annexin V assay) at the indicated time points (n = 3) (E). Thapsigargin is presented by solid lines and nontreated cells by dashed lines. (F) 
Dispersed human islet cells were transfected with si1 or siCT for 48 hours and exposed or not to brefeldin A for 24 hours. Apoptosis was evaluated by staining with 
DNA-binding dyes (n = 4). (G and H) EndoC-βH1 cells were transfected with si1 or siCT for 48 hours and exposed to thapsigargin for the indicated times (n = 5–6). 
CHOP (G) and DP5 (H) mRNA expression was measured by qPCR, normalized to β-actin (ACTB). (I and J) EndoC-βH1 cells were transfected with siCT or si1 and/or 
siRNA against CHOP (siCHOP) (I) or DP5 (siDP5) (J) and treated or not with thapsigargin for 40 hours (n = 5 and n = 8, respectively). Apoptosis was examined by 
DNA-binding dye. Individual symbols represent independent experiments, and box plots show the median by a horizontal line, 25th and 75th percentiles at the 
bottom and top of the boxes, and minimum and maximum values by whiskers. In time course experiments, data are shown as mean ± SEM. Paired 2-way ANOVA 
or mixed-model analysis (in case of missing values) followed by Bonferroni post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. siCT in respective condition; ##P < 
0.01, ###P < 0.001 for treated vs. untreated cells; †††P < 0.001 as indicated.
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was found in both progenitor (ventricular zone) and neuronal 
(intermediate zone and cortical plate) compartments. Some 
selective expression could also be detected within the choroid 
plexus within the cerebral ventricles. No significant signal was 
observed with sense probes, confirming the specificity of the 
findings (Figure 2B).
YIPF5 deficiency sensitizes human β cells to ER stress–induced 
apoptosis. To investigate the effect of YIPF5 loss in β cells, we 
established an in vitro model of YIPF5 deficiency using RNA inter-
ference in human EndoC-βH1 cells. YIPF5 was efficiently silenced 
using 2 different siRNAs by 50%–75% at the mRNA level (Figure 
3A and Supplemental Figure 2) and by approximately 50% at the 
protein level (n = 2–4).
YIPF5 depletion did not impact β cell function: glucose- 
and forskolin-stimulated insulin secretion was comparable in 
YIPF5-depleted and -competent EndoC-βH1 cells, as was insulin 
content (Figure 3, B and C). Furthermore, YIPF5 depletion did not 
affect proliferation rates of EndoC-βH1 cells, assessed by Ki67 
immunostaining (data not shown).
Survival of β cells was evaluated under basal condition and 
following exposure to the ER stressors brefeldin A (which blocks 
ER-to-Golgi transport) and thapsigargin (which inhibits the sarco/
endoplasmic reticulum Ca2+ ATPase [SERCA]). YIPF5 knockdown 
did not significantly affect basal β cell survival, but YIPF5-deplet-
ed β cells were markedly sensitized to thapsigargin (Figure 3D). 
This was confirmed by a second apoptosis assay that measures 
annexin V binding in real time, showing that thapsigargin induced 
more apoptosis in cells transfected with either YIPF5 siRNA (Fig-
ure 3E). Brefeldin A treatment markedly induced YIPF5 mRNA 
expression in EndoC-βH1 cells and human islets (Supplemental 
Figure 2, A and B); a trend for YIPF5 protein induction was seen 
in EndoC-βH1 cells (approximately 2-fold; n = 4). YIPF5 silencing 
enhanced apoptosis in brefeldin-treated clonal β cells and human 
islets (Figure 3, D and F), in keeping with the presumed function of 
YIPF5 in ER-to-Golgi trafficking.
YIPF5 deficiency increases human β cell ER stress signaling and 
induces proapoptotic proteins PUMA and DP5. We next investigat-
ed whether YIPF5 deficiency affects ER stress signaling by mea-
suring mRNA expression of CHOP, spliced XBP1 (sXBP1), BiP, 
PDIA4, and HYOU1, which act in the 3 canonical branches of 
the ER stress response (downstream of PERK, IRE1, and ATF6, 
respectively). Time course experiments in EndoC-βH1 cells 
exposed to thapsigargin showed that YIPF5 knockdown induced 
ER stress markers (Figure 3G and Supplemental Figure 2, C–F). 
The induction was more pronounced for PERK- and ATF6-depen-
dent markers, while the IRE1 target sXBP1 was induced to a lesser 
extent. In brefeldin-treated cells, YIPF5 silencing also enhanced 
ER stress signaling (data not shown). Taken together, these results 
show that YIPF5 deficiency potentiates the ER stress response.
The BH3-only proteins PUMA (also known as BBC3), DP5 
(also known as HRK), and BIM (also known as BCL2L11) activate 
apoptosis downstream of ER stress, playing a central role in β cell 
demise (26–29). In time course experiments, DP5 expression was 
induced by YIPF5 silencing in thapsigargin-exposed (Figure 3H) 
and brefeldin-exposed cells (data not shown). PUMA expression 
was also induced by YIPF5 silencing (Supplemental Figure 2G), 
while BIM expression was not altered.
In order to examine whether the induction of CHOP, a 
proapoptotic transcription factor in the PERK branch of the ER 
stress response, sensitizes YIPF5-deficient β cells to apoptosis, 
we double-knocked-down CHOP and YIPF5 (Figure 3I and Sup-
plemental Figure 2H). CHOP silencing protected YIPF5-depleted 
cells from thapsigargin (Figure 3I), and similarly, DP5 and YIPF5 
double knockdown (Supplemental Figure 2I) partially protected β 
cells from thapsigargin-induced apoptosis (Figure 3J).
Proinsulin accumulation, increased ER stress signaling, and 
reduced insulin content in YIPF5-knockout stem cell–derived β cells. To 
study the role of YIPF5 in the development and function of pancre-
atic β cells, we used CRISPR/Cas9 technology to generate a YIPF5 
knockout (KO) in the human embryonic stem cell (hESC) line H1. 
We deleted exon 3, which is common to all the YIPF5 isoforms (Sup-
plemental Figure 3, A and B). The YIPF5-KO cell line expressed 
pluripotency markers as expected and showed a normal karyotype 
(Supplemental Figure 4, A–C) with no evidence of CRISPR-induced 
off-target indels (data not shown). In addition to the KO, we gen-
erated an isogenic YIPF5Ile98Ser mutation using CRISPR/Cpf1–medi-
ated homology-directed repair (HDR) (Supplemental Figure 5). 
This is the same mutation present in the 2 siblings in family III, who 
were both diagnosed with diabetes after the age of 6 months. The 
H1 wild-type (WT), KO, and YIPF5Ile98Ser cells differentiated nor-
mally until the pancreatic endocrine stage. At this stage, proinsulin 
accumulation was evident in the KO β cells (Figure 4A and Supple-
mental Figure 6A). The percentage of cytoplasmic area stained for 
proinsulin per β cell of the KO was 5.5-fold higher than in their WT 
counterparts, while the percentage of insulin area was 70% less in 
the KO β cells (Figure 4C). The YIPF5Ile98Ser β cells showed a much 
milder phenotype with 20% less insulin area and a 1.7-fold increase 
in proinsulin area compared with the WT; however, the differences 
were not statistically significant. A 15-fold increase was detected 
in the number of cells with high BiP immunoreactivity (INS+BiPhi) 
in the KO (Figure 4, B and D; and Supplemental Figure 6B), likely 
reflecting ER stress response triggered by proinsulin retention in the 
ER. Consistent with this, the KO cells showed significant induction 
of BiP and HYOU1 mRNA expression at stage 7 of differentiation, 
but not of ATF6, XBP1s, and CHOP (Supplemental Figure 7). INS 
mRNA expression was significantly reduced at stages 6 and 7 in the 
KO (Supplemental Figure 7), although there was no difference in the 
percentage of INS+ cells in the 3 cell lines (Figure 4H). In the KO β 
cells, no increase in apoptosis was detected by TUNEL assay at stage 
7, but the cells were more sensitive following exposure to chemical 
ER stressors, especially brefeldin A (Figure 4E). Stem cell–derived β 
cells of all 3 lines showed glucose-stimulated insulin secretion, but 
the absolute amount of secreted insulin was 50% lower in the KO 
cells (Figure 4F), and cellular insulin content was reduced by 80% 
(Figure 4G). Transmission electron microscopy was used to study 
the ultrastructure of the stem cell–derived endocrine cells. The ER 
morphology identified by the studded ribosomes along its outer 
membrane showed a marked distension of the ER cisternae in all 
of the studied KO β cells, while the ER in α cells was not affected. 
ER dilation was observed in only a minority of the YIPF5Ile98Ser β cells 
(Figure 4I and Supplemental Figure 8).
Loss of β cell function after in vivo implantation. Stage 7 islet-like 
aggregates differentiated from WT, KO, and YIPF5Ile98Ser H1 stem 
cells were implanted under the kidney capsule of immunocom-
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lines (2 from each patient) had normal karyotype, expressed plu-
ripotency markers, lost the expression of the exogenous transgene 
vector, and successfully differentiated into the 3 germ layers in 
an embryoid body assay (Supplemental Figure 10, A–E). For one 
patient iPSC line, we corrected the mutation by CRISPR/Cpf1 and 
generated 2 isogenic control iPSC lines (Supplemental Figure 5A). 
These corrected iPSCs had normal morphology and karyotype and 
expressed pluripotency markers (Supplemental Figure 5, D–F).
The YIPF5 patients’ iPSCs differentiated into stage 7 islet 
cells with somewhat fewer insulin-positive cells and slightly more 
glucagon-expressing cells compared with healthy control or cor-
rected iPSCs (Figure 6, A and B). The expression of genes during 
differentiation was comparable between patients’ and control and 
corrected iPSC lines, with a trend for lower INS mRNA expression 
at stages 6 and 7 (Supplemental Figure 11). The p.(Ile98Ser) muta-
tion did not affect proinsulin and insulin content (Supplemental 
Figure 12, A and B) nor glucose- and/or forskolin-stimulated insu-
lin secretion (Supplemental Figure 12C).
The viability of YIPF5 patient β cells was less than that of 
healthy or corrected β cells (Figure 6C). Similarly, caspase-3/7 
activation tended to be higher in patients’ iPSC-β cells compared 
with corrected β cells (n = 2–5; data not shown). Following 48–72 
hours of exposure to the ER stressor thapsigargin, tunicamycin, 
or brefeldin A, YIPF5-mutant cells tended to be more prone to 
undergo apoptosis (Figure 6, C and D). Contrary to the YIPF5-KO 
H1 cells, ER stress signaling was not enhanced by the p.(Ile98S-
er) mutation in patient iPSC- or hESCp.(Ile98Ser)-β cells under basal 
condition (Figure 6E). Induction of CHOP and BiP mRNA expres-
sion upon tunicamycin exposure tended to be higher in patients’ 
β cells compared with healthy control and patient corrected β 
cells (Figure 6E). In keeping with the results in YIPF5-depleted 
EndoC-βH1 cells, the proapoptotic BCL-2 family members DP5 
and PUMA were induced in ER-stressed YIPF5-mutant cells 
(Figure 6E). Taken together, our results demonstrate that the 
p.(Ile98Ser) YIPF5 mutation does not compromise differentia-
tion and function of β cells but affects cell survival by sensitizing 
them to ER stress–induced apoptosis.
Discussion
We report 6 patients from 5 families with a congenital syndrome 
of neonatal/early-onset diabetes, severe microcephaly, and epi-
lepsy caused by biallelic mutations in the YIPF5 gene. Morpho-
logical and functional studies show that YIPF5 is expressed during 
human brain development and in adult brain and pancreatic islets 
and that YIPF5 deficiency reduces β cell survival by enhancing 
the ER stress response and sensitizing human β cells to ER stress–
induced apoptosis.
The clinical features identified in the 6 patients were very sim-
ilar, with all of them having severe microcephaly and early-onset 
epilepsy. All had diabetes, with the age at diagnosis ranging from 
the neonatal period to early infancy. The disease severity was 
variable between families, with 5 affected individuals in family 
II dying in early infancy (the homozygous YIPF5 mutation could 
be confirmed only in the proband, as DNA was not available from 
siblings), while patient I is reported to have normal neuromotor 
development at the age of 5 years and his epilepsy resolved at 
the age of 2 years. The missense mutation identified in patient I, 
promised NOD/SCID-γ mice, and their function was monitored 
by measurement of the serum levels of human C-peptide. While 
the WT-implanted mice reached a level of 1 nM at 3 months, 
human C-peptide was barely detectable in the KO-implanted 
mice, consistent with impaired β cell function. Lower C-peptide 
levels were also recorded in the YIPF5Ile98Ser-implanted mice after 
1, 2, and 3 months (Figure 5A). Blood glucose levels in the WT-im-
planted mice dropped from 8 to 4 mM 3 months after implanta-
tion, reflecting glycemic regulation by transplanted human β cells, 
while no such effect was observed in the KO- or YIPF5Ile98Ser-im-
planted mice (Figure 5B).
The grafts were retrieved for immunohistochemical analysis 
3 months after implantation. Insulin- and glucagon-positive cells, 
which were the dominant cell types, were quantified. In the WT 
and YIPF5Ile98Ser grafts, 55% and 42% of the cells were insulin-pos-
itive, respectively. In contrast, glucagon-positive cells dominated 
in the KO grafts, where only 12% of the grafted cells were insu-
lin-positive (Figure 5, C and F). The mature β cells in the KO and 
YIPF5Ile98Ser grafts showed a 3.3- and 3-fold reduction, respectively, 
in the percentage of cytoplasmic insulin-positive area, and a 5.7- 
and 5.4-fold increase, respectively, in the proinsulin area (Figure 
5, D and G). The accumulated proinsulin colocalized with the ER 
proteins calreticulin, BiP, and GRP170 (Supplemental Figure 9). 
The insulin-positive KO cells sustained high BiP expression in vivo, 
consistent with persistent ER stress. Grafts of YIPF5Ile98Ser-mutant 
aggregates also showed clear signs of increased ER stress when 
harvested at 3 months after implantation (Figure 5, E and H). No 
difference was detected in the number of TUNEL+ cells in the 
grafts (data not shown).
β Cells from patients’ induced pluripotent stem cells harboring the 
p.(Ile98Ser) mutation are sensitive to ER stress–induced apoptosis. To 
further assess the impact of one of the YIPF5 missense mutations in 
a directly patient-relevant model, we generated patients’ induced 
pluripotent stem cells (iPSCs) and differentiated them into pan-
creatic endocrine cells. PBMCs were obtained from patients IIIa 
and IIIb, who are both homozygous for the p.(Ile98Ser) mutation, 
and reprogrammed into iPSCs using Sendai virus. The 4 iPSC 
Figure 4. Proinsulin accumulation, increased ER stress signaling, and 
reduced insulin content in YIPF5-knockout stem cell–derived β cells. (A) 
Immunocytochemistry for proinsulin (PROINS) and insulin (INS) at stage 
7 of in vitro differentiation for WT and YIPF5-KO cells. Scale bars: 25 μm. 
(B) Immunocytochemistry for BiP and insulin (INS) at stage 7 of in vitro 
differentiation. Scale bars: 25 μm. (C) Percentage of cytoplasmic area cov-
ered by proinsulin or insulin per insulin-positive cell (n = 3). (D) Percentage 
of INS+BiPhi cells per total number of INS+ cells (n = 4–8). (E) Percentage of 
apoptotic cells (INS+TUNEL+) per total number of INS+ cells after treatment 
with vehicle (DMSO) and the ER stressors thapsigargin, tunicamycin, 
and brefeldin A (n = 3–5). (F) Static glucose-stimulated insulin secretion 
at stage 7 normalized to micrograms DNA of β cells (n = 3–7). (G) Insulin 
content of stage 7 differentiated cells normalized to micrograms DNA of β 
cells (n = 3–8). (H) Percentage of INS+ cells at week 2 of stage 7 (n = 3–4). 
Statistical significance was assessed in C, D, G, and H by 1-way ANOVA 
test with Bonferroni correction, and in E and F by 2-way ANOVA test with 
Bonferroni correction. **P < 0.01, ***P < 0.001, ****P < 0.0001. Error bars 
represent SD from the mean. (I) Transmission electron microscopy of WT, 
YIPF5-KO, and YIPF5Ile98Ser stage 7 cells showing the cytoplasmic area of β 
and α cells. Yellow arrowheads point at insulin granules, red arrowheads at 
glucagon granules, and green arrowheads at ER. Scale bars: 1 μm.
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HeLa cells. Among the residues investigated were p.Gly97 and 
p.Ile98, which are mutated in families III and V. Substitutions at 
these positions were not found to result in whorl formation in the 
study by Dykstra et al. (35). Consistent with this, we did not observe 
whorl formation in hESCp.(Ile98Ser)-β cells, supporting the previous-
ly suggested notion that whorl formation is uncoupled from other 
YIPF5 functions (35) and our hypothesis that the mutations identi-
fied in our patients do not completely abolish YIPF5 function. To 
try to account for this possibility in our functional experiments, we 
used a model of complete loss of function (complete KO in hESCs), 
as well as models of incomplete loss of function [50%–75% knock-
down in human EndoC-βH1 cells, iPSCs derived from 2 of the cas-
es with the p.(Ile98Ser) mutation, and hESCs harboring the same 
homozygous p.(Ile98Ser) mutation].
In all 3 partial loss-of-function models, YIPF5 deficiency result-
ed in increased expression of ER stress markers upon treatment 
with the ER stressors thapsigargin, tunicamycin, and brefeldin A, 
with a tendency to increase apoptosis. In EndoC-βH1 cells, YIPF5 
expression was strongly upregulated by brefeldin A, which blocks 
ER-to-Golgi transport, suggesting that transcriptional induction 
of YIPF5 could be part of a compensatory mechanism to over-
come the inhibition of trafficking. Further studies will be needed 
in order to elucidate which pathways regulate YIPF5 expression 
in response to ER stressors such as brefeldin A and whether Golgi 
stress response transcription factors such as CREB3 (36) and TFE3 
(37) are involved. Taken together, our results support YIPF5’s role 
in ER-to-Golgi transport and point toward YIPF5 loss sensitizing 
β cells to ER stress–induced apoptosis. In HeLa cells, YIPF5 has 
been shown to interact with and promote IRE1 oligomerization 
and phosphorylation and enhance downstream XBP1 splicing 
upon tunicamycin exposure or infection with Brucella abortus 
(38). In HeLa and CaSki cells, another human cervical cancer cell 
line, YIPF5 constitutively activated IRE1 and PERK signaling, 
with YIPF5-depleted cells showing reduced IRE1 phosphoryla-
tion, lower PERK mRNA and protein expression, and less PERK 
phosphorylation and downstream signaling (39). These contrast-
ing findings suggest that YIPF5 may impact ER stress and the ER 
stress response in a cell type– and/or context-dependent manner.
As expected, the most striking phenotype was observed when 
the YIPF5 gene was completely knocked out in hESCs. These KO 
β cells showed a strong increase in the proinsulin/insulin ratio, 
consistent with proinsulin not being transported into the Golgi, 
and triggered the ER stress response. Furthermore, transmission 
electron microscopy of YIPF5-KO β cells and α cells showed a pro-
nounced ER distension in the KO β cells resulting from ER stress 
induced by proinsulin accumulation in the ER. In contrast, the ER 
in YIPF5-KO α cells was not affected, suggesting that YIPF5 is spe-
cifically essential for proinsulin trafficking from the ER in β cells.
The milder phenotype observed in patient-iPSC- and 
ESCp.(Ile98Ser)-derived β cells might indicate that the YIPF5 protein 
harboring the p.(Ile98Ser) mutation still maintains some residual 
activity, which is consistent with the 2 patients being diagnosed 
with diabetes in early infancy (rather than at birth) and having low 
but measurable C-peptide levels more than 10 years after diabetes 
diagnosis (Table 1). However, ESCp.(Ile98Ser)-derived islet-like aggre-
gates showed a significant decrease in human C-peptide levels 
associated with increased proinsulin accumulation and signs of 
p.(Ala181Val), was predicted to be tolerated by 2 of 4 in silico tools 
used, suggesting the possibility that this variant has a less severe 
effect on protein function. It is therefore possible that this pheno-
typic variability is directly linked to the severity of the mutation; 
however, our cohort of patients with homozygous YIPF5 muta-
tions is currently too small to allow accurate estimation of any 
genotype-phenotype relationship.
YIPF5 is a 5-span transmembrane protein (Figure 1B) that 
cycles between the ER and the Golgi and localizes at ER exit sites, 
the ER-Golgi intermediate compartment, and part of the cis-Gol-
gi (30–33). Previous studies in HeLa cells have suggested that 
YIPF5 plays a role in cargo exit from the ER (34), resulting in pro-
tein overload, thereby triggering the ER stress response. This was 
consistent with data in yeast reporting delayed ER-to-Golgi trans-
port when a dominant-negative form of the YIPF5 ortholog Yip1A 
was overexpressed (33). Other studies did not detect delayed 
anterograde cargo transport when silencing YIPF5 expression 
and instead found evidence for a role of YIPF5 in retrograde Gol-
gi-to-ER transport (30, 31). ER whorling and partial Golgi frag-
mentation have also been observed in in vitro models of YIPF5 
depletion, suggesting a role of YIPF5 in ER and Golgi structure 
maintenance (30, 32–34).
The mutations identified in our patients affect different 
regions of the YIPF5 protein, 3 of them located in the cytoplas-
mic domain, which is likely to be important for interactions with 
other proteins, and the other 2 predicted to affect residues in the 
transmembrane domains. All these mutations are predicted to be 
deleterious; however, it is possible that function of the YIPF5 pro-
tein is not completely lost. YIPF5 knockdown in HeLa cells has 
been previously reported to result in reorganization of the ER into 
stacked, concentric, whorl-like structures (34). The same group lat-
er investigated the effect of a comprehensive range of amino acid 
substitutions in YIPF5 (35). They reported that even single-residue 
substitutions of amino acids located in the third and fourth trans-
membrane domains (which include the p.Ala181 and p.Trp218 res-
idues mutated in families I and IV) severely compromised protein 
stability. These results thereby support the likely pathogenicity of 
the p.(Ala181Val) and p.(Trp218Arg) variants we have identified, 
possibly through impaired protein stability. Dykstra et al. (35) iden-
tified 5 YIPF5 residues (3 cytoplasmic and 2 in the transmembrane 
domain) that, when mutated, resulted in ER whorl formation in 
Figure 5. Reduced C-peptide secretion and β cell numbers in implanted 
YIPF5 knockout and signs of YIPF5Ile98Ser β cell failure. (A) Human C-pep-
tide levels measured in mouse serum through 3 months after implan-
tation (n = 3–8). (B) Mouse blood glucose levels at 1 and 3 months after 
implantation (n = 3–10). (C) Percentage of INS+GCG– cells per the total 
number of INS+ plus GCG+ cells (n = 3–5). (D) Percentage of cytoplasmic 
area covered by proinsulin or insulin in insulin-positive cells (n = 3–4). 
(E) Percentage of INS+BiPhi cells per total number of INS+ cells (n = 3–6). 
(F–H) Immunohistochemistry of grafts for glucagon (GCG) and insulin 
(INS) (F), proinsulin (PROINS) and insulin (INS) (G), and BiP and insulin 
(INS) (H) 3 months after implantation. Scale bars: 100 μm (F); 25 μm (G); 
100 μm (H, left); 25 μm (H, right). Statistical significance was assessed 
by 2-way ANOVA test with Bonferroni correction in A, by multiple t test 
with Bonferroni correction in B, and by 1-way ANOVA test with Bonferroni 
correction in C–E. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.00001. 
Error bars represent SD from the mean.
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cerebral cortex development (44, 45). As an example, Zika virus 
infection has been shown to cause microcephaly by inducing ER 
stress; inhibition of PERK prevents microcephaly in Zika virus–
infected mouse embryos (45).
One potential explanation for YIPF5’s essential role in β cell 
survival is its interaction with components of the COPII vesicle coat 
protein complex (sec23 and sec24) that mediates COPII-depen-
dent export and the anterograde transport from the ER to the Gol-
gi (33). This pathway plays a vital role in ER homeostasis and β cell 
survival, with inhibition of Sar1, which initiates COPII assembly, 
causing alterations in ER morphology and severe ER stress in β cells 
(46). Consistent with this, ER morphology was severely affected in 
YIPF5-KO hESC-β cells, but we did not observe the whorl-like struc-
tures described in YIPF5-deficient HeLa cells (34), suggesting that 
phenotypic specificity may be due to YIPF5 cell-specific functions. 
The specific importance of YIPF5 for β cells is further supported by 
our observation that expression of ER stress markers in islet aggre-
gates derived from YIPF5-KO hESCs was limited to the β cells, while 
α cells had normal glucagon expression and no ER stress. These 
data strongly suggest that while β cells are highly dependent on 
YIPF5 function, α cells appear to be able to survive without YIPF5.
While disruption of ER-to-Golgi trafficking is known to result 
in at least 10 different neurological disorders (47), its involvement 
in the etiology of diabetes has been less clear. Recently a trun-
cating mutation in the TANGO1 (MIA3) gene, encoding a protein 
involved in the export of bulky cargos from the ER to the Golgi, 
has been reported in one consanguineous family with a complex 
syndrome of dentinogenesis imperfecta, short stature, skeletal 
abnormalities, sensorineural hearing loss, and mild intellectual 
disability. All 4 affected individuals also had insulin-dependent 
diabetes, highlighting the importance of the mechanisms regulat-
ing cargo exit from the ER for β cell function (48). A β cell–spe-
cific knockout of cTAGE5, a TANGO1-interacting protein, has 
been previously shown to impair proinsulin trafficking, induce ER 
stress, and cause impaired glucose tolerance in mice (49). Further-
more, impaired ER-to-Golgi trafficking may play a role in β cell 
dysfunction and death caused by environmental insults in type 
2 diabetes, as exposure of β cells to the saturated free fatty acid 
palmitate reduces protein trafficking, thereby contributing to ER 
stress (19). The molecular mechanisms by which palmitate exerts 
these effects remain to be fully elucidated.
In conclusion, we report homozygous mutations in YIPF5 as 
the genetic cause of an autosomal recessive syndrome character-
ized by microcephaly, epilepsy, and neonatal/early-onset diabe-
tes. Functional studies show that YIPF5 deficiency affects β cell 
function by enhancing ER stress and sensitizing human β cells to 
ER stress–induced apoptosis. To the best of our knowledge, this is 
the first report of mutations in a gene affecting ER-to-Golgi traf-
ficking resulting in diabetes by increasing β cell ER stress, uncov-
ering a critical role of YIPF5 in the human β cell. Our findings high-
light a biological pathway essential for β cells.
Methods
Further information can be found in Supplemental Methods.
Patient cohort. Patients with neonatal diabetes were recruited by 
their clinicians for molecular genetic analysis in the Exeter Molecular 
Genetics Laboratory.
ER stress after implantation, demonstrating the evolution of cel-
lular pathology with further maturation of the stem cell–derived 
β cells. It is possible that the complete absence of YIPF5 protein 
leads to a more drastic phenotype, as seen in Yipf5 knockout in 
mice, which is postnatally lethal (40). In addition, the human 
YIPF5 gene appears to be intolerant to loss-of-function variants 
based on gnomAD gene constraints (pLI = 0.99), further support-
ing that loss-of-function variants are likely strongly deleterious in 
humans. More functional experiments and identification of fur-
ther patients are needed to test these hypotheses.
YIPF5 is widely expressed across tissues (Figure 2A). Our 
qPCR analysis detected abundant expression in pancreatic tissue, 
islets, β cells, and brain (Figure 2A). Previous expression studies of 
swine YIPF5 showed expression in adipose tissue and spleen, but 
low expression in intestine, liver, lung, muscle, and kidney; pan-
creatic tissue was not tested (41). While ubiquitously expressed 
in human tissues, (partial) YIPF5 loss of function caused by the 
mutations results in a β cell– and brain-specific phenotype in the 
patients, possibly pointing to YIPF5 cargo specificity; it will be of 
interest to examine this in future studies.
The YIPF5 expression pattern we observed in human embry-
onic brain, showing high expression in progenitor and neuro-
nal compartments of the developing cortex in addition to the 
choroid plexus within the cerebral ventricles, is consistent with 
YIPF5 playing a role in neural progenitors and/or neurons during 
development of the cerebral cortex, which is mostly affected by 
primary microcephaly. The expression in the choroid plexus is in 
line with potential control of brain morphogenesis and size, as 
this structure was recently found to secrete important morpho-
gens and growth factors during embryonic brain development 
(42, 43). Physiological ER stress controls cortical neurogenesis 
(44), and sustained ER stress causes microcephaly by perturbing 
the normal generation and survival of projection neurons during 
Figure 6. iPSCs from patients IIIa and IIIb differentiated into β cells are 
sensitive to ER stress–induced apoptosis. (A) Representative immunos-
taining of dispersed stage 7 aggregates stained for insulin (INS, green) and 
glucagon (GCG, red). Nuclei were visualized with DAPI (blue). (B) Quan-
tification of immunostained cells (expressed as percent of total cells) in 
dispersed stage 7 control (n = 25) and patient cells (n = 11). Blue squares 
represent patient cells (2 patients, 2 iPSC lines for each); black circles 
and squares represent healthy control (1 iPSC line) and corrected patient 
cells (2 iPSC lines from 1 patient), respectively. (C and D) Apoptosis was 
assessed by staining with DNA-binding dyes in vehicle- (DMSO-)treated, 
thapsigargin-treated, and tunicamycin-treated control and corrected 
(n = 10) and patient (n = 6–7) stage 7 aggregates (C) or by luminescence 
produced by annexin V binding in time course experiments (means ± SEM; 
n = 10 control and corrected lines and n = 5 patient lines) (D). (E) mRNA 
expression of CHOP, BiP, sXBP1, DP5, and PUMA assessed by qPCR in stage 
7 aggregates from control and corrected (n = 4–8, black) and patient cells 
(n = 5–7, blue) exposed for 48 hours to vehicle (DMSO), thapsigargin, or 
tunicamycin. mRNA expression was normalized to the geometric mean of 
reference genes β-actin and GAPDH. The median is shown by a horizontal 
line in the box plots; 25th and 75th percentiles are at the bottom and top 
of the boxes; whiskers represent minimum and maximum values, and data 
points independent experiments. Comparisons were done by multiple t 
test followed by Bonferroni’s correction for multiple comparisons (B), ANO-
VA followed by Bonferroni’s correction for multiple comparisons (C and D), 
and paired-ratio t test (E). *P < 0.05, **P < 0.01, ***P < 0.001 treatment 
vs. DMSO; #P < 0.05, ##P < 0.01 vs. control and corrected cells as indicated.
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cATGCTGGCTATGACTAATC-3′, reverse 5′-ggtggtggtaccAAATCT-
GCATGAGAG-3′, in which SacI and KpnI restriction sites (highlighted 
in bold) were added to allow the directional cloning of the probe into 
pBluescript II SK(+) plasmid. Sense and antisense probes were gener-
ated by transcription of the KpnI or SacI linearized plasmid with T3 or 
T7 RNA polymerases, respectively.
Genome editing of hESCs and iPSCs. For knocking out the YIPF5 
gene in H1 hESCs, the third exon was deleted using 2 CRISPR/
Cas9 guides that were designed with Benchling (Biology Software, 
2019) (G1.1 GGCTATGACTATTCGCAGCA and G1.2 GATGAGC-
CACCTTTATTAGA). The ribonucleoprotein (RNP) components 
(HiFi Cas9 protein, crRNA and tracrRNA) were purchased from Inte-
grated DNA Technologies (IDT) and prepared based on the manufac-
turer’s protocol. Two million cells were electroporated with the RNP 
complex using Neon Transfection System (1100 V, 20 milliseconds, 2 
pulses, Thermo Fisher Scientific) and single-cell-cloned using limiting 
dilution. The sequence of the primers used to screen the formed col-
onies is provided in Supplemental Table 5. The KO cell line was char-
acterized for pluripotency using immunocytochemistry for OCT4, 
TRA1-60, and SSEA4, and for gene expression levels of OCT4, SOX2, 
and NANOG by qPCR.
CRISPR/Cpf1 was used to correct the mutation p.(Ile98Ser) in 
the patient iPSC line ULBi006.SA7 and to introduce the mutation 
p.(Ile98Ser) in WT H1 hESCs using homology-directed repair (HDR). 
An isogenic control for the patient iPSCs was generated using a 
21-base guide, CCAGATGTGGTCAAAATTGCT, while the guide for 
introducing the mutation in H1 was CCAGATGTGGTCAAAATTGAT. 
The correction and mutation templates were generated as a 200-bp 
PCR amplicon using 110-base forward and reverse primers (see Sup-
plemental Table 5 for sequence).
The templates were designed to introduce silent mutations to 
generate a restriction site to facilitate the screening of the clones using 
restriction enzymes. The restriction site for the correction template 
was PfeI, while BamHI was created for the mutation template. The 
RNP components (Alt-R A.s. Cpf1 Ultra and crRNA) were purchased 
from IDT and prepared based on the manufacturer’s protocol. The 
cells were electroplated as mentioned before with 2 μg HDR template, 
then single-cell-sorted and screened using PCR (see Supplemental 
Table 5 for primer sequence), followed by enzyme restriction. Positive 
clones were confirmed using Sanger sequencing at Eurofins Genom-
ics, and the sequences were aligned using Geneious Prime 2020.1.1. 
The top 3 off-target hits predicted by the online tool CRISPOR (56) 
were checked, and no off-target indels were found (see Supplemental 
Table 5 for primer sequence).
hESC culturing, differentiation into β cells, and chemical ER-stress 
induction. The H1 hESCs were obtained from WiCell, Wisconsin 
Materials [provider scientist, Maike Sander, University of California; 
stock WA01 (H1)]. Differentiation of hESCs to pancreatic endocrine 
cells was performed using published protocols (57–59) with further 
modifications. Cells were seeded at a density of 1.8 million cells per 
3.5 cm well on Matrigel-coated plates with E8 medium containing 10 
μM ROCK inhibitor. Differentiation was started 24 hours later and 
proceeded through a 7-stage differentiation protocol (stages 1–4 in 
adherent culture, stage 5 in AggreWell [34421, Stemcell Technolo-
gies], and stages 6 and 7 in suspension culture). After 1 week of stage 7, 
50 hESC-derived islet-like aggregates were transferred into a 12-well 
plate in 1 mL of stage 7 medium with brefeldin A (B5936, Sigma-Al-
Genetic analysis. Genome sequencing was performed on DNA 
extracted from peripheral blood leukocytes of 2 probands diagnosed 
with neonatal diabetes, microcephaly, and epilepsy. Samples were 
sequenced on an Illumina HiSeq 2500 with a mean read depth of 38.3 
for patient I and 33.6 for patient II. The sequencing data were ana-
lyzed using an approach based on the GATK best practice guidelines. 
GATK HaplotypeCaller (https://gatk.broadinstitute.org/hc/en-us/
articles/360037225632-HaplotypeCaller) was used to identify vari-
ants that were annotated using Alamut batch version 1.8 (Interactive 
Biosoftware), and variants that failed the QD2 VCF filter or had less 
than 5 reads supporting the variant allele were excluded. Copy num-
ber variants were called by SavvyCNV, which uses read depth to judge 
copy number states. SavvyVcfHomozygosity was used to identify large 
(>3 Mb) homozygous regions in the genome sequencing data (https://
github.com/rdemolgen/SavvySuite).
Replication studies were performed in a cohort of 187 patients 
diagnosed with diabetes before age 12 months in whom the known 
genetic causes of neonatal diabetes had been excluded. Patients were 
analyzed using a targeted next-generation sequencing assay (50), 
which includes baits for known neonatal diabetes genes and addition-
al candidate genes followed up from gene discovery, such as YIPF5, or 
by independent exome sequencing analysis. Variant confirmation and 
cosegregation in family members were performed by Sanger sequenc-
ing (see Supplemental Table 4 for primer sequence).
The bioinformatics tools SIFT, PolyPhen-2, MutationTaster, and 
Align GVGD were accessed through the Alamut software (Interactive 
Biosoftware) to predict the effect of variants on the YIPF5 protein.
Human β cell and islet culture and treatment. Human insulin-pro-
ducing EndoC-βH1 cells, provided by R. Scharfmann (Institut Cochin, 
Université Paris Descartes, Paris, France), were cultured as previously 
described (51, 52). EndoC-βH1 cells were exposed to 1 μM thapsigargin 
or 0.05 μg/mL brefeldin A in medium containing 2% FBS. All com-
pounds were from Sigma-Aldrich. The vehicle DMSO was added to the 
control condition in all experiments.
Human islets from nondiabetic organ donors (n = 4, 2 female 
and 2 male donors; age 62 ± 9 years; BMI 27 ± 3 kg/m2; cause of 
death: 3 cerebral hemorrhage, 1 cardiovascular disease) were isolat-
ed by collagenase digestion and density gradient purification, and 
cultured as previously described (53). The percentage of β cells of 
the human islet preparations was 59% ± 5%, as determined by insu-
lin immunofluorescence.
RNA interference. YIPF5 was silenced using 2 siRNAs targeting 
different sequences of YIPF5 (si1 SI04182745 and si2 SI04344984, 
Qiagen). CHOP was silenced using SI3041633 (Qiagen) and DP5 
using s194952 (Ambion). Allstar Negative Control siRNA (siCT, Qia-
gen) was used as negative control. This siRNA does not affect β cell 
gene expression, function, or viability (54). Transient transfection 
was performed using 30 nM siRNA and Lipofectamine RNAiMAX 
lipid reagent (Invitrogen/Life Technologies) as previously described 
(54). After overnight transfection, cells were cultured at least 8 hours 
before treatment.
RNA in situ hybridization. In situ hybridization on human fetal 
brain tissue was performed using digoxigenin-labeled RNA probes 
(DIG RNA labeling kit, Roche) as previously described (55). The ribo-
probe template was designed to target the first 764 nucleotides of the 6 
different splice variants of human YIPF5. The template was amplified 
by PCR using human YIPF5-specific primers: forward 5′-ggtggtgagct-
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patient, namely, ULBi006.SA2 and ULBi006.SA7, ULBi007.BA2 
and ULBi007.BA11) were used as well as a previously characterized 
control cell line (HEL115.6) (63). The differentiation into β cells was 
done as previously described (62, 63). Cells were seeded at 2.5 × 106 
cells per 3.5 cm well in E8 medium containing 5 μM ROCK inhibitor 
(Stemcell Technologies). Differentiation was started 24 hours later. 
Until the pancreatic progenitor stage (stage 4), cells were differentiat-
ed in Matrigel-coated wells, after which they were plated in microwell 
plates at 900 cells per microwell (AggreWell) to form islet-like aggre-
gates. The differentiation was continued in microwells. After 1 week of 
stage 7, aggregates were exposed to 1 μM thapsigargin, 5 μg/mL tuni-
camycin, or 0.01 μg/mL brefeldin A in stage 7 medium. DMSO was 
used as vehicle control.
Insulin content and secretion. EndoC-βH1 cells were preincubated 
in DMEM containing 2.8 mM glucose for 24 hours, followed by incuba-
tion in glucose-free Krebs solution for 1 hour. Cells were then exposed 
to Krebs containing 0 mM or 20 mM glucose or 20 mM glucose plus 
10 μM forskolin for 40 minutes. Insulin was measured in cell-free 
supernatants and acid-ethanol–extracted cell lysates, the latter nor-
malized for total protein content measured by Bradford dye method. 
Fifty hESC-derived stage 7 aggregates were washed twice with glu-
cose-free Krebs buffer and preincubated on a rotating platform with 
1 mL 3.3 mM glucose-containing Krebs buffer for 1 hour. Aggregates 
were incubated sequentially in 3.3 mM glucose, 20 mM glucose, and 
3.3 mM plus 30 mM KCl for periods of 30 minutes. Supernatants were 
stored at −80°C for ELISA. Aggregates were lysed by sonication and 
acid-ethanol for determination of insulin and DNA contents. Insu-
lin secretion results are presented as insulin released after cell mass 
normalization using DNA content of the β cell percentage assessed 
by FACS. Forty iPSC-derived stage 7 aggregates were washed with 
glucose-free Krebs buffer (Univercell Biosolutions) in low-adhesion 
plates (83.1836, Starstedt) and preincubated in 1.6 mM glucose Krebs 
for 30 minutes. Aggregates were exposed to 1.6 mM glucose, 16.7 mM 
glucose, or 16.7 mM glucose plus 10 μM forskolin for 1 hour. Hormone 
content was normalized for total protein content.
ELISA. Human C-peptide, proinsulin, and insulin levels were 
measured from plasma samples and cell supernatants and lysates with 
Ultrasensitive C-peptide, proinsulin, and insulin ELISAs (all from 
Mercodia, Sweden) according to the manufacturer’s instructions.
Statistics. Statistical analyses were performed with GraphPad Prism 
(version 7.0c, GraphPad Software). Data points represent independent 
experiments. In secretion experiments, data points represent the aver-
age of biological duplicates. In the box plots, the median is shown by a 
horizontal line; 25th and 75th percentiles are at the bottom and top of 
the boxes; whiskers represent minimum and maximum values. In time 
course experiments, data are shown as mean ± SEM. For the EndoC-β1 
and iPSC experiments, comparisons between groups were performed 
by paired 2-way ANOVA or mixed-model analysis (in case of a missing 
value), followed by 2-tailed t tests with the Bonferroni correction for 
multiple comparisons. For hESC experiments, the parametric unpaired 
2-tailed t test and 1-way and 2-way ANOVA tests with the Bonferroni 
multiple-comparisons test were used to compare the sum of ranks. P val-
ues less than 0.05 were considered statistically significant.
Study approval. The genetic study in the Exeter Molecular Genet-
ics Laboratory was conducted in accordance with the Declaration of 
Helsinki, and all patients or their parents gave informed consent for 
genetic testing.
drich) at 1 μg/mL for 24 hours, thapsigargin (T9033, Sigma-Aldrich) 
and tunicamycin (T7765, Sigma-Aldrich) at 1 μM and 5 μg/mL, respec-
tively, for 48 hours. DMSO was used as a vehicle control at 5 μL/mL. 
Aggregates were PFA-fixed for immunohistochemistry.
Transplantation of differentiated cells. NOD/SCID-γ mice (005557, 
The Jackson Laboratory) were obtained from SCANBUR and housed 
at Biomedicum Helsinki animal facility, on a 12-hour light/12-hour 
dark cycle and food ad libitum. Transplantations were performed on 
3- to 9-month-old mice as described previously (60). Briefly, aggre-
gates equivalent to approximately 3 million cells were loaded on 
PE-50 tubing and transplanted under the kidney capsule. Mice were 
anesthetized with isoflurane. Carprofen (5 mg/kg, subcutaneously; 
Rimadyl, Pfizer, Helsinki, Finland) and buprenorphine (0.05–0.1 mg/
kg, subcutaneously; Temgesic, RB Pharmaceuticals Ltd.) were used as 
analgesics during the operation and the following day. Mouse blood 
samples were collected monthly from the saphenous vein using hep-
arinized capillary tubes. Plasma was separated by centrifugation at 
5000 RCF for 5 minutes at room temperature.
PBMC reprogramming into iPSCs and iPSC quality control. PBMCs 
from patients IIIa and IIIb were reprogrammed into iPSCs using Sen-
dai virus. Cells were plated in RPMI with 10% FBS (Gibco) at 106 cells 
per well of a 6-well low-attachment plate (3471, Corning) and infected 
the next day with SeVdp (KOSM302L) vector (22MAT1411, Nation-
al Institute of Advanced Industrial Science and Technology, Tokyo, 
Japan) at MOI 2 for 2 hours. Medium was refreshed with E6 medium 
(Gibco), and cells were transferred to Matrigel-coated plates (Corn-
ing BV, Life Sciences). From day 8, cells were cultured in E8 medi-
um (Life Technologies) and medium was changed every second day. 
Emerging iPSC colonies were manually picked up. Vector removal was 
confirmed by reverse-transcriptase PCR with the following primers: 
5′-AGACCCTAAGAGGACGAAGACAGA-3′ and 5′-ACTCCCATGG-
CGTAACTCCATAG-3′. For the embryoid body assay, iPSCs reaching 
60%–70% confluence were detached with 0.5 mM EDTA (Life Tech-
nologies), resuspended in E8 medium containing 10 μM ROCK inhibi-
tor (Stemcell Technologies), and transferred to super-low-attachment 
plate (Corning) on a rotating platform to form aggregates. The next 
day, embryoid bodies were resuspended in DMEM/F-12 medium 
(Gibco) containing Glutamax (Gibco), 10% KSR (Life Technologies), 
1% NEAA (Thermo Fisher Scientific), 0.1 mM β-mercaptoethanol 
(Gibco), and 1% penicillin/streptomycin. Medium was changed every 
second day for 1 week. Embryoid bodies were plated on Matrigel-coat-
ed ICC chambers (15–20 per well) for 2 weeks, with medium refreshed 
every second day, and fixed in PFA 4% for immunocytochemistry. For 
karyotyping, KaryoMax Colcemid solution (Gibco 15210) was added 
to 80% confluent iPSCs at a final concentration of 500 ng/mL for 
3–4 hours at 37°C. Cells were washed with PBS, incubated in Trypsin/
EDTA solution (R001100, Thermo Fisher Scientific) at room tem-
perature for 2 minutes, detached, collected in DMEM/F-12 with 10% 
FBS (Gibco), centrifuged for 10 minutes at 300 g, and resuspended in 
0.0075 M KCl. After 10 minutes of incubation, cells were centrifuged 
at 600 g for 10 minutes and resuspended in the fixative methanol/ace-
tic acid 3:1 (Merck). After 20 minutes, cells were washed twice with 
the fixative and stored at 4°C. Karyotyping was done at the Institute of 
Pathology and Genetics, Gosselies, Belgium.
iPSC culturing and differentiation into β cells. iPSCs were cultured 
in Matrigel-coated plates (Corning) in E8 medium as previously 
described (61, 62). Four YIPF5 mutant cell lines (2 clones from each 
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Human pancreata not suitable for clinical purposes were collect-
ed from nondiabetic, brain-dead organ donors after written informed 
consent from next of kin, and handled as described (64) with the 
approval of the Ethical Committee, University of Pisa.
The human fetal brain study was approved by the Ethics Com-
mittee of Erasmus Hospital, Université Libre de Bruxelles. Written 
informed consent was given by the parents.
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was given by patients or parents with approval by the Erasmus Hospi-
tal Ethics Committee (ref. P2008/313). Written informed consent for 
inclusion of patient photographs in scientific publications was collect-
ed by the referring clinicians from one parent of each patient.
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